The Absence of LPA2 Attenuates Tumor Formation in an Experimental Model of Colitis-Associated Cancer

Gastroenterology

Volumn 136, Issue 5, 2009, Pages 1711-1720

  Lin, Songbai ^a   Wang, Dongsheng ^a   Iyer, Smita ^a   Ghaleb, Amr M ^a   Shim, Hyunsuk ^a   Yang, Vincent W ^a   Chun, Jerold ^b   Yun, C Chris ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLOOXYGENASE 2; KRUPPEL LIKE FACTOR 5; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 2; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; AZOXYMETHANE; CYTOKINE; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COLITIS; COLON ADENOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE DELETION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; C57BL MOUSE; COLON TUMOR; DISEASE COURSE; DRUG EFFECT; METABOLISM; MOUSE MUTANT; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; AZOXYMETHANE; BETA CATENIN; CELL PROLIFERATION; CHEMOKINE CCL2; COLITIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYTOKINES; DISEASE PROGRESSION; GENES, APC; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIPOPOLYSACCHARIDES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 65249173527     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.01.002     Document Type: Article

References (48)

1. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol 287 (2004) G7-G17
2. Ye X., Ishii I., Kingsbury M.A., et al. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 1585 (2002) 108-113
3. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3 (2003) 582-591
4. van Meeteren L.A., and Moolenaar W.H. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46 (2007) 145-160
5. van Corven E.J., Groenink A., Jalink K., et al. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59 (1989) 45-54
6. Xu Y., Shen Z., Wiper D.W., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280 (1998) 719-723
7. Goetzl E.J., Dolezalova H., Kong Y., et al. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 59 (1999) 5370-5375
8. Nakamoto T., Yasuda K., Yasuhara M., et al. Expression of the endothelial cell differentiation gene 7, a lysophosphatidic acid receptor, in ovarian tumor. J Obst Gyn Res 31 (2005) 344-351
9. Shida D., Watanabe T., Aoki J., et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 84 (2004) 1352-1362
10. 2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol 289 (2005) C2-C11
11. Contos J.J.A., Fukushima N., Weiner J.A., et al. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A 97 (2000) 13384-13389
12. 2. Mol Cell Biol 22 (2002) 6921-6929
13. 3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435 (2005) 104-108
14. Huang M.C., Lee H.Y., Yeh C.C., et al. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 23 (2004) 122-129
15. Pretlow T.P., Barrow B.J., Ashton W.S., et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 51 (1991) 1564-1567
16. Suzuki R., Kohno H., Sugie S., et al. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 95 (2004) 721-727
17. Huang M.C., Graeler M., Shankar G., et al. Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta 1582 (2002) 161-167
18. Papanikolaou A., Wang Q.S., Papanikolaou D., et al. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21 (2000) 1567-1572
19. Yang M., Zhong W.W., Srivastava N., et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the (beta)-catenin pathway. Proc Natl Acad Sci U S A 102 (2005) 6027-6032
20. Zhang H., Bialkowska A., Rusovici R., et al. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J Biol Chem 282 (2007) 15541-15549
21. Mori K., Kitayama J., Shida D., et al. Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. J Surg Res 132 (2006) 56-61
22. Li C., Dandridge K.S., Di A., et al. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. J Exp Med 202 (2005) 975-986
23. Deng W., Tsukahara S.E., Valentine W.J., et al. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132 (2007) 1834-1851
24. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53 (2002) 35-57
25. Fang X., Yu S., Bast R.C., et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian caner cells. J Biol Chem 279 (2004) 9653-9661
26. Zhao Y., He D., Saatian B., et al. Regulation of lysophosphatidic acid- induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase C δ, Lyn kinase, and matrix metalloproteinases. J Biol Chem 281 (2006) 19501-19511
27. Moser A.R., Dove W.F., Roth K.A., et al. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 116 (1992) 1517-1526
28. Reya T., and Clevers H. Wnt signalling in stem cells and cancer. Nature 434 (2005) 843-850
29. Fang X., Yu S., Tanyi J.L., et al. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22 (2002) 2099-2110
30. Ghaleb A.M., Nandan M.O., Chanchevalap S., et al. Kruppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res 15 (2005) 92-96
31. Chen Q., Olashaw N., and Wu J. Participation of reactive oxygen species in the lysophosphatidic acid-stimulated mitogen-activated protein kinase kinase activation pathway. J Biol Chem 270 (1995) 28499-28502
32. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
33. Symowicz J., Adley B.P., Woo M.M.M., et al. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 65 (2005) 2234-2242
34. Oyesanya R.A., Lee Z.P., Wu J., et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J 22 (2008) 2639-2651
35. Shida D., Kitayama J., Yamaguchi H., et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63 (2003) 1706-1711
36. Salcedo R., Ponce M.L., Young H.A., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
37. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 4 (2004) 540-550
38. Tanaka S., Tatsuguchi A., Futagami S., et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 55 (2006) 54-61
39. Popivanova B.K., Kitamura K., Wu Y., et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118 (2008) 560-570
40. Meyer-Siegler K.L., Vera P.L., Iczkowski K.A., et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 8 (2007) 646-652
41. Legendre H., Decaestecker C., Nagy N., et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 16 (2003) 491-504
42. Wilson J.M., Coletta P.L., Cuthbert R.J., et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129 (2005) 1485-1503
43. Sun B., Nishihira J., Yoshiki T., et al. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 11 (2005) 1050-1058
44. Hudson J.D., Shoaibi M.A., Maestro R., et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190 (1999) 1375-1382
45. Maaser C., Eckmann L., Paesold G., et al. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterology 122 (2002) 667-680
46. Hasegawa Y., Erickson J.R., Goddard G.J., et al. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 278 (2003) 11962-11969
47. Virag T., Elrod D.B., Liliom K., et al. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol 63 (2003) 1032-1042
48. Ohta H., Sato K., Murata N., et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64 (2003) 994-1005